This week (January 17-23), important events in the pharmaceutical industry include: the relay market of therapeutic drugs after covid-19 test flameout; The pharmaceutical patent pool organization of the public health organization under the United Nations announced that it would sign agreements with 27 API and preparation enterprises around the world, including 5 Chinese enterprises; Guangdong Provincial Drug Trading Center issued the document of Guangdong Alliance for centralized procurement of diclofenac and other drugs (hereinafter referred to as the document), and launched alliance centralized procurement of 276 drugs, including growth hormone and blood products.
The details are as follows:
covid-19
Covid-19 detection of therapeutic drugs after flameout?
On January 17, the covid-19 test sector, which was hot in the early stage, completely stalled today, and several stocks appeared on the decline list; However, related therapeutic drug stocks did not fall with the above sectors. Sinolink Securities Co.Ltd(600109) the report suggests that we can pay attention to five main epidemic lines at present: ① small molecule cdmo industrial chain and its upstream of fine chemicals; ② Epidemic detection, mainly covid-19 detection kit suppliers; ③ Other upstream supply chains related to covid-19, including suppliers of antigens, antibodies, enzymes, plasmids, etc; ④ Epidemic related innovative drug R & D enterprises; ⑤ Other epidemic related, such as vaccine R & D enterprises and other anti epidemic equipment / consumables suppliers.
The share price of enterprises that have obtained the “special imitation” right of MSD covid-19 drugs rose first, but it is not easy to “make a lot of money”
On the 20th, the medicines patent pool (MPP), a public health organization affiliated to the United Nations, announced that it would sign agreements with 27 API and preparation enterprises around the world, which could produce molnupiravir, an oral covid-19 drug, without royalties during “public health emergencies”, And sell to 105 low – and middle-income countries (excluding China) (subject to authorization by local regulators).
Among the 27 “special imitations” list, there are five Chinese enterprises, namely: Langhua Pharmaceutical (only API can be provided), Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) (600196. SH), Longze pharmaceutical, Brightgene Bio-Medical Technology Co.Ltd(688166) (688166. SH) and desaino (the last four can provide API and preparation).
The most profitable new shares were born during the year: n Chengda was outstanding in the breaking tide, and the maximum profit of single signing exceeded 50000 yuan
On January 20, n Chengda landed on the gem. After the “calm” morning trading, the company’s share price rose rapidly in the afternoon, once soared by nearly 150%. The temporary stop was triggered twice in the session, and finally closed up 76.85% to 128.55 yuan / share. If the intraday increase is the largest, the single signature can earn up to 53700 yuan. Even in the case of the recent breaking of new pharmaceutical shares, Chengda pharmaceutical has been able to stand out and become the new share with the highest single signing income during the year.
Chengda pharmaceutical is mainly engaged in cdmo services for key pharmaceutical intermediates, and is also a provider of barretinib API; From the perspective of scientific mechanism, barretinib has therapeutic effect on severe covid-19.
industry depth
The first shot of growth hormone collection! Strength exceeded expectations, leading enterprises responded to the limit
On January 19, Guangdong Pharmaceutical Trading Center issued the document of Guangdong Alliance for centralized procurement of diclofenac and other drugs (hereinafter referred to as the document), which launched the Alliance for centralized procurement of 276 drugs, including growth hormone and blood products.
Blood products were included in the centralized collection for the first time: the market “flashed” emotional panic, and the industry said that the impact was limited
Ice and fire song of stock price and performance will CXO be good in 2022?
Recently, a number of CXO head companies have predicted their performance in 2021 and achieved rapid growth, but this does not seem to lead to the stabilization and rebound of stock prices. The resumption of CXO market in 2021 can be basically divided into four stages——
At the beginning of 2021, under the expectation of accelerated performance, the CXO industry showed a good upward trend, and the valuation increased accordingly.
However, after the Spring Festival, the pharmaceutical sector as a whole fluctuated downward, and the CXO sector with high overvalued value in the early stage had the most callback.
In the mid-term report quarter of 2021, the high performance expectation of the mid-term report will once again raise the market’s attention to CXO. However, on July 2, 2021, the CDE of the National Drug Evaluation Center issued the draft for comments on the guiding principles for clinical research and development of antitumor drugs guided by clinical value, which raised doubts about the outlook of CXO in the market, resulting in slight fluctuations in the overall sector.
In the second half of 2021, the capital style switched, the pharmaceutical sector entered the adjustment period, and the overvalued CXO sector retreated greatly. At the same time, the investment and financing data of the primary market fell quarter on quarter, superimposing the breaking of many listed pharmaceutical enterprises in the second half of the year, causing the market to worry about the demand for CXO outsourcing.
issued and approved by science and technology innovation board
The first share of gene therapy cdmo is registered through the science and innovation board. How much space is left for car-t enterprises to build their own production line?
According to the official website of the CSRC, we agree to register the initial public offering of shares on the science and Innovation Board of Heyuan Biotechnology (Shanghai) Co., Ltd. (hereinafter referred to as “Heyuan biotechnology”). This also means that the science and innovation board is expected to usher in the first share of gene therapy cdmo. Founded in 2013, Heyuan biology is an enterprise providing cro and cdmo services for gene therapy. Among them, cdmo business for gene therapy start-ups is the main line of its development. From 2018 to 2020, the proportion of cdmo business income of Heyuan biological gene therapy in the main business income was 29.79%, 39.51% and 71.47% respectively, showing an accelerated growth trend.
Core products or intellectual property disputes, can the IPO of Yifang biotechnology innovation board be smoothly promoted? Star capital such as Hillhouse has made bets
Due to the existence of intellectual property disputes, recently, the listing application of Yifang Biotechnology (Shanghai) Co., Ltd. (hereinafter referred to as Yifang Biotechnology) on the science and Innovation Board was “suspended” by the municipal Party Committee on the science and innovation board. However, Yifang biology subsequently clarified that the patents involved would not have a significant adverse impact on the company; The reporter of science and Innovation Board daily further investigated and learned that it is still difficult to judge whether it will have a significant adverse impact.
primary market
Shanghai biomedical fund exclusively leads investment Baiquan biology
Shanghai Baiquan Biotechnology Co., Ltd. (hereinafter referred to as “Baiquan biotechnology”) recently announced the completion of an angel round of financing of tens of millions of yuan. This round of financing is led by Shanghai biomedical fund and followed by dart accelerator (Atlas). Baiquan biology was founded in Shanghai Lingang Holdings Co.Ltd(600848) in December 2020. The company built biotroy engine, an integrated platform for the discovery of new tumor immune targets, and fully verified the function of the new targets to independently mediate tumor immune escape and the corresponding development value of translational medicine through systematic studies such as clinical proteomics and receptor proteomics.
At the same time, the company has built extremely high patent barriers, protected new targets from multiple levels, and completed the platform construction of target biology, antibody discovery and upstream process development, ensuring the comprehensive competitive advantage of the company.
Shanghai biomedical fund exclusively led the investment, and Yuguo biology completed a financing of 300 million yuan
Yuguo biology announced that it had completed the round C financing of RMB 300 million, which was exclusively invested by Shanghai biomedical fund and followed by the old shareholder lyfe ZhouLing capital. The funds raised in this round will continue to be invested in new product R & D and in-hospital localization deployment of pathogenic ngs. Established in February 2017, Yuguo biology is the first enterprise in China to transform cell free mngs into clinical practice, and is one of the few teams with self-developed algorithm ability.
Aurora Borealis venture capital invested in manlang medical to complete the pre-A round of financing
Manlang medical, which focuses on comprehensive psychiatric diagnosis and evidence-based psychotherapy services, today announced that with the support of Aurora Borealis venture capital, it has completed the pre-A round of strategic financing and independent spin off, laying a solid foundation for accelerating growth in the future.
Manlang medical was officially established in China in 2020. Relying on the mature clinical service products and operation system of 18 psychiatric institutions of green leaf medical group in Australia, with the continuous support of clinical, psychological and management experts of Australian institutions, combined with the strategic cooperation and expert support of well-known psychiatric institutions in China, manlang medical has established 6 institutions in Shanghai, Shenzhen, Guangzhou and Xi’an, And online internet medical service platform, offline institutions and online internet medical services are beginning to take shape.
CPE Yuanfeng and Guoshou science and innovation fund jointly led the investment of silicon-based bionics and completed the financing of over RMB 800 million Series C
Shenzhen silicon-based Bionics Technology Co., Ltd. (hereinafter referred to as “silicon-based bionics”) has completed a C + + round of financing of more than 500 million yuan, which is jointly led by CPE Yuanfeng and Guoshou science and Innovation Fund under Guoshou investment company, followed by Qianhai master fund, Jianfa Xinxing investment, Jingming capital and old shareholders Luxin Venture Capital Group Co.Ltd(600783) . In addition to the previous c-round financing of over RMB 100 million led by source capital, sunshine Ronghui and Luxin Venture Capital Group Co.Ltd(600783) follow-up investment, and the C + round financing of over RMB 100 million led by Dachen Caizhi, and followed by Fubai capital and source capital, silicon-based bionics has completed three consecutive rounds of c-series financing of over RMB 800 million in the past year. This round of financing will be used for technology upgrading, marketing and new product line development of CGM products.
From the perspective of product layout, silicon based bionics has always focused on the research and industrialization of medical active implantation and medical AI. Business includes continuous glucose monitoring system (CGM), diabetic retinopathy auxiliary diagnostic software, artificial retina and capsule gastroscopy Siasun Robot&Automation Co.Ltd(300024) . On November 4, 2021, GS1 silicon-based dynamic continuous glucose monitoring system developed by silicon-based bionics passed the approval of the State Drug Administration, becoming the first domestic finger free blood calibration continuous glucose monitoring system, which is the current key business of silicon-based bionics.
Sinopharm capital changed its name to “Jianyi capital”, focusing on the five subdivided fields of medicine and health
On the 19th, the former Sinopharm capital announced to change its name to “Jianyi capital”, focusing on the five fields of new molecular technology, innovative biotherapy, innovative equipment, precision diagnosis and treatment and intelligent medical treatment, so as to create a pharmaceutical equity investment institution with distinctive characteristics of “CVC + IVC”. Wu Aimin, the founding managing partner and President of Jianyi capital, the renamed Sinopharm capital, said that Jianyi capital will promote the investment strategy of “innovation + integration” and continue to build the core competitiveness driven by “industry + capital”.
